Cormedix INC Form 4 insider transactions

CorMedix Inc. CEO Joseph Todisco exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 plan.

CorMedix Inc.'s CEO, Joseph Todisco, disposed of 21,225 common shares at $11.66 each, a transaction reported late due to an administrative error.

CorMedix Chief Legal Officer Beth Zelnick Kaufman exercised stock options and subsequently sold a significant portion of her common stock holdings.

CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, exercised stock options and subsequently sold shares in pre-planned transactions.

CorMedix Chief Operating Officer Elizabeth Hurlburt filed an amended Form 4 to correct an omission regarding the withholding of 8,424 common shares for tax liability.

CorMedix Inc.'s Chief Legal Officer, Beth Zelnick Kaufman, filed an amended Form 4 to correct an omission regarding shares withheld for tax liability.

CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, was granted 69,686 restricted stock units, aligning her interests with long-term company performance.

CorMedix Inc.'s Chief Legal Officer, Beth Zelnick Kaufman, was granted 69,686 restricted stock units, increasing her beneficial ownership to 189,298 shares.

CorMedix Inc.'s Chief Financial Officer, Susan Blum, was granted 69,686 Restricted Stock Units, vesting over four years.

Director Steven W. Lefkowitz acquired 20,000 shares of CorMedix Inc. common stock through the exercise of stock options on April 2, 2025.

CorMedix CEO Joseph Todisco exercised stock options to acquire 59,170 shares of common stock at $3.38 per share on April 1, 2025.

CorMedix CEO Joseph Todisco acquired 187,500 shares of restricted stock and disposed of 23,977 shares to cover tax obligations on January 17, 2025.

Director Alan W. Dunton of CorMedix Inc. acquired 25,000 restricted stock units on January 17, 2025, which will vest on January 17, 2026.

Director Robert A. Stewart of CorMedix Inc. acquired 25,000 restricted stock units on January 17, 2025, which will vest on January 17, 2026.

Director Janet Dillione of CorMedix Inc. acquired 25,000 restricted stock units on January 17, 2025, which will vest on January 17, 2026.

Director Myron Kaplan of CorMedix Inc. acquired 25,000 restricted stock units on January 17, 2025, which will vest on January 17, 2026.

Director Steven W. Lefkowitz of CorMedix Inc. acquired 25,000 restricted stock units on January 17, 2025, which will vest on January 17, 2026.

Director Gregory Scott Duncan of CorMedix Inc. was granted 25,000 restricted stock units on January 17, 2025, which will vest on January 17, 2026.

CorMedix CFO Matthew T. David sold 6,515 shares of common stock on January 10, 2025, to cover tax obligations.

CorMedix CEO Joseph Todisco sold 17,829 shares of common stock on January 10, 2025, to cover tax obligations related to vesting of shares.

Erin Mistry, EVP and Chief Commercial Officer of CorMedix Inc., sold 5,689 shares of common stock on January 10, 2025, to cover tax obligations.

Elizabeth Hurlburt, Executive Vice President of CorMedix Inc., sold 5,790 shares of common stock on January 10, 2025, to cover tax obligations.

EVP and Chief Commercial Officer of CorMedix, Erin Mistry, reports acquisition of 62,500 shares of common stock and disposition of 7,830 shares on January 2, 2025.

Elizabeth Hurlburt, Executive Vice President of CorMedix Inc., reports the acquisition of 87,500 restricted stock units and the disposal of 11,378 shares for tax purposes.

CorMedix CFO Matthew T. David acquired 62,500 shares of common stock through restricted stock units and disposed of 8,648 shares to cover tax obligations on January 2, 2025.

CorMedix Inc.'s Chief Legal Officer, Beth Zelnick Kaufman, reported the acquisition of 87,500 restricted stock units and the disposal of 11,844 shares for tax purposes on January 2, 2025.

CorMedix's Chief Legal Officer, Beth Zelnick Kaufman, amended a previous SEC filing to correct the number of shares owned after a transaction.

CorMedix's Chief Legal Officer, Beth Zelnick Kaufman, reported the acquisition of 12,500 shares of common stock and the disposition of 6,044 shares to cover tax obligations.

CorMedix EVP, Chief Commercial Officer Erin Mistry purchased 1,500 shares of company stock at $9.9899 per share on October 31, 2024.

Elizabeth Hurlburt, an EVP at CorMedix Inc., executed multiple stock options and sold a significant number of shares on November 14, 2024.